Dydrogesterone has no peripheral (anti)-androgenic properties.
Dydrogesterone, an orally effective progestational compound, frequently used in a large spectrum of endocrine and gynecologic problems was evaluated for possible peripheric androgenic or anti-androgenic activity. The drug was tested in vivo in the hamster flank organ test and in vitro in tests based on molecular mechanisms of androgen action. Dydrogesterone appeared to have neither androgenic nor anti-androgenic properties. This is important in view of the fact that dydrogesterone can also be indicated during pregnancy.
Vermorken
A J
AJ
INSERM U-58, Biochimie des Stéroïdes, Montpellier, France.
Sultan
C
C
Goos
C M
CM
D058891:5-alpha Reductase Inhibitors; D000728:Androgens / Q000378:metabolism*; D002478:Cells, Cultured; D004394:Dydrogesterone / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006197:Hair / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism*
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D011944:Receptors, Androgen; D004394:Dydrogesterone